Guidelines Update | Summary of 2026 NCCN Ovarian Cancer Guidelines (V1–V4)
The National Comprehensive Cancer Network (NCCN) has rolled out four consecutive iterations of its Clinical Practice Guidelines for ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), releasing Versions 1 through 4. Each update targets the core of clinical practice: a strategic rollback of PARP inhibitors, a reconstruction of recurrence treatment logic, the formal inclusion of immunotherapy, the filling of gaps in rare tumors, and a complete overhaul of pathological definitions... This represents a multi-faceted reshaping of treatment philosophy and clinical pathways. To help you grasp these changes at a glance, we have strictly cross-referenced the original texts to provide a complete summary of all updates across the four versions.
PART 01 | Core Directions of Change Across All Versions
The updates across the four 2026 versions collectively point toward a treatment logic that aligns more closely with real-world evidence. Overall, the guidelines have completed a critical transition—from "broad-spectrum targeting" to "precision stratification," and from "empirical therapy" to "mechanism-driven therapy."
(1) A Strategic Rollback in the Positioning of PARP Inhibitors
In previous guidelines, PARP inhibitors were widely recommended for recurrent disease. However, the 2026 version explicitly removes them entirely from both platinum-sensitive and platinum-resistant recurrent settings, stably retaining them only as first-line maintenance therapy. This adjustment is highly consistent with recent overall survival (OS) data and FDA indication withdrawals, ensuring PARP inhibitor use returns to the patient populations most likely to benefit.
(2) HRD Testing Shifts from "Strong Recommendation" to "Rational Interpretation"
The new guidelines clarify that current HRD testing is merely a functional surrogate marker and does not fully reflect the true state of homologous recombination function. It also emphasizes that patients with HRP (Homologous Recombination Proficient) tumors derive minimal benefit from PARP inhibitors, fundamentally narrowing the scope of drug use guided by HRD status.
(3) Comprehensive Upgrade in Platinum-Resistant Recurrent Treatment
The previous paradigm dominated by rotating single-agent chemotherapies has been broken. Immunotherapy combination regimens are now formally included as preferred options, and novel targeted combinations have been rapidly approved and incorporated into the guidelines. For the first time, platinum-resistant ovarian cancer possesses a more efficient and standardized treatment system.
(4) Unified Pathological Terminology
The guidelines officially abolish the potentially misleading term "LMP (Low Malignant Potential)" in favor of "Borderline Tumors." It is emphasized that these are not "low-risk tumors" but an independent tumor type with clear progression risks requiring long-term follow-up.
(5) First Systematic Improvement in Rare Ovarian Cancer Diagnosis and Treatment
Notably, the complete diagnostic, staging, treatment, and follow-up pathways for Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) have been added, filling a significant clinical gap.
PART 02 | Updates by Version
V1.2026 (Released Feb 25, 2026): Global and Structural Revision
(Figure 1 Source: NCCN)
V1 represents the most significant structural update of 2026, reconstructing the entire framework for recurrence and maintenance therapy.
Recurrent Treatment:
Both platinum-sensitive and platinum-resistant diseases saw massive reductions in recommended regimens.
Platinum-Sensitive: Melphalan and oral Etoposide were deleted. All three PARP inhibitors (Niraparib, Olaparib, Rucaparib) were removed as Category 3 recommendations. Bevacizumab was downgraded from "Preferred" to "Other Recommended."
Platinum-Resistant: Melphalan and the three PARP inhibitors were similarly deleted; oral Etoposide was downgraded, and Bevacizumab was also downgraded.
Breakthroughs: Immunotherapy achieved a major breakthrough. Paclitaxel plus Pembrolizumab ± Bevacizumab became an option. For clear cell carcinoma, a dual immunotherapy regimen of Ipilimumab plus Nivolumab was specifically added.
First-Line Maintenance Therapy:
Clear, unified stratification rules were established for the first time. The applicable population is limited to Stage II–IV high-grade serous carcinoma, Grade 2–3 endometrioid carcinoma, and clear cell carcinoma or carcinosarcoma harboring BRCA mutations.
BRCA-mutated or HRD-positive: PARP inhibitors may be used as monotherapy or in combination with Bevacizumab.
BRCA wild-type and HRP: PARP inhibitors are no longer recommended; observation or continuation of Bevacizumab maintenance is advised.
Pathology & Biomarkers:
V1 abolished the LMP terminology, replacing it with Borderline Tumors, emphasizing that 15–20% of serous borderline tumors progress to low-grade serous carcinoma. New criteria for differentiating primary ovarian mucinous carcinoma from gastrointestinal metastases were added (PAX8, SATB2, tumor size >13 cm). The guidelines clarified minimal PARP inhibitor benefit for HRP patients and defined PD-L1 positivity as CPS ≥ 1.
Other Updates:
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with cisplatin was added as an option for initial treatment. A subcutaneous formulation of Pembrolizumab was introduced. Hormone Replacement Therapy (HRT) was deemed permissible for symptom relief in high-grade serous carcinoma following evaluation. The full diagnostic and treatment pathway for SCCOHT was formally integrated.
V2.2026 (Released Mar 12, 2026): Precision Corrections for Rare Tumors
(Figure 2 Source: NCCN)
V2 was a minor yet critical precision update focused on SCCOHT. The guideline deleted Tazemetostat from the preferred recurrence treatment options and removed the associated references, aligning recommendations for this rare tumor more closely with the latest evidence.
V3.2026 (Released Mar 30, 2026): Clarification of Maintenance Therapy Notes
(Figure 3 Source: NCCN)
V3 consisted of annotation corrections, primarily refining the duration of PARP inhibitor maintenance therapy:
If CR (Complete Remission) has not been achieved after 2 years of treatment: Continuation of Olaparib or Rucaparib is permitted.
If CR has not been achieved after 3 years of treatment: Continuation of Niraparib or Rucaparib is permitted.
This revision provides greater standardization for long-term maintenance decisions.
V4.2026 (Released Apr 10, 2026): Incorporation of Latest Blockbuster Regimens
(Figure 4 Source: NCCN)
V4 is the most immediate update relevant to clinical practice, focusing on adding a new preferred regimen for platinum-resistant recurrence.
Based on Phase III ROSELLA trial results and FDA approval, Albumin-bound Paclitaxel combined with Relacorilant officially became a preferred treatment for platinum-resistant ovarian cancer.
This regimen significantly reduces the risk of death by 35% and is applicable to platinum-resistant patients who have received ≤3 lines of systemic therapy and at least one line containing Bevacizumab. It is specifically noted that glucocorticoid premedication is strictly prohibited. This update rapidly translates high-level evidence into clinical recommendations.
PART 03 | Summary
Through four consecutive updates (V1–V4), the 2026 NCCN Ovarian Cancer Guidelines have completed a modernized reshaping of the diagnosis and treatment system. The overarching trends can be summarized into three points:
1. Sharper Therapeutic Focus
PARP inhibitors have definitively returned to the first-line maintenance setting and are no longer routinely used in recurrence, concentrating therapeutic resources on the populations most likely to benefit.
2. More Aggressive Treatment for Resistant Disease
Platinum-resistant ovarian cancer has moved beyond the era of simple chemotherapy rotation into a new era of "immunotherapy combinations + novel targeted therapies." Refractory types, such as clear cell carcinoma, have also gained dedicated immunotherapy options.
3. More Rigorous Diagnostics and Stratification
Unified pathological terminology, rational interpretation of HRD, and standardized management of rare tumors make clinical decision-making more scientific, safer, and reproducible.
For clinical practice, the core insight of the 2026 guidelines is: Biomarker-based precision stratification outperforms broad-spectrum targeted therapy; evidence-based iterative updates outperform empirical prescribing. Moving forward, ovarian cancer diagnosis and treatment will continue to advance along the path of "greater precision, greater standardization, and greater individualization."
[This article is intended for medical professionals for learning and communication purposes only and should not be used as a basis for specific clinical operations. Actual clinical decisions must combine patient conditions, institutional capabilities, and the latest guidelines, with multidisciplinary consultation initiated when necessary.]
Editor: Lily